Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer completes acquisition of Visible Genetics:

This article was originally published in Clinica

Executive Summary

Bayer Diagnostics (Tarrytown, New Jersey) has completed its $61.4m acquisition of Visible Genetics of Toronto, Canada (see Clinica No 1017, p 19). The purchase will enable Bayer to market Visible Genetics' Trugene HIV-1 genotyping test for HIV drug resistance alongside its own Versant family of HIV nucleic acid diagnostics tools, including the recently approved HIV-11 RNA 3.0 assay for viral load testing. Bayer expects the worldwide market for infectious disease testing to grow by 20% per year, reaching $1bn by 2005.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT068560

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel